PLB 1003 / Avistone Biotech - LARVOL DELTA

Preliminary Results of Second Generation ALK Inhibitor PLB1003: A Phase La Study (IASLC-WCLC 2019) - P1; "PLB1003 is safe, tolerable and has potential clinical benefit to locally advanced or metastatic NSCLC patients with ALK rearrangement mutation and had disease progression or were intolerable to previously treatment of Crizotinib or chemtherapy. (ClinicalTrials.gov number, NCT03130881)"

Phase I Study of a Selective ALK Inhibitor PLB1003 in Patients With ALK+ NSCLC. (clinicaltrials.gov) - P1; N=60; Recruiting; Sponsor: Beijing Pearl Biotechnology Limited Liability Company; Trial completion date: Jun 2019 ➔ Dec 2021; Trial primary completion date: Jun 2018 ➔ Dec 2020

Clinical • Trial completion date • Trial primary completion date

Newly added product (clinicaltrials.gov) - P1, Non Small Cell Lung Cancer.

Pipeline update